Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Biohaven Ltd. (BHVN)
USD14.92
-0.25 (-1.65%)
US NYSE Healthcare Biotechnology
Address
215 Church Street 6510
New Haven, CT, US
New Haven, CT, US
CEO
Vladimir Coric
Website
biohaven.com
IPO
2022-09-23
CIK 1935979 ISIN VGG1110E1079
Description
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD14.92
-0.25 (-1.65%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
3.14
Float Shares
84.69M
Free Float %
80.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.52% | +15.89% | +14.81% | -4.43% | +9.77% | -2.48% | -25.66% | -32.37% | +50.82% | +50.82% | +50.82% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (25 ratings, all time)
Buy
Price Targets & DCF
Current price
14.92
Low
10.00
-33.0%
Consensus
17.60
+18.0%
Median
18.00
+20.6%
High
23.00
+54.2%
Ratings Trend (MoM)
74% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 10 | 0 |
| Hold | 5 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
18.00
+20.6%
|
| Last Quarter | 3 |
14.33
-4.0%
|
| Last Year | 9 |
19.78
+32.6%
|
| All Time | 26 |
43.19
+189.5%
|
Quality scores
Altman Z-Score
-8.34
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+26.1% Q1'26: +59.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-6,252.7% Q1'26: -842.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+18.0% Q1'26: +44.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.38× Q1'26: -0.55× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 11 EPS Ana. |
Dec 2027 12 Rev. Ana. 11 EPS Ana. |
Dec 2028 16 Rev. Ana. 15 EPS Ana. |
Dec 2029 15 Rev. Ana. 10 EPS Ana. |
Dec 2030 15 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 426.10M (-100.0%)
|
—
est: 820.28M (-100.0%)
|
—
est: 7.69M (-100.0%)
|
—
est: 285.7K (-100.0%)
|
2.45M
2.00M – 2.90M
+758.0% YoY
|
16.94M
11.75M – 22.12M
+591.0% YoY
|
89.18M
85.57M – 92.78M
+426.5% YoY
|
277.90M
227.05M – 328.73M
+211.6% YoY
|
719.46M
587.81M – 851.05M
+158.9% YoY
|
| EBITDA |
-217.51M
est: -479.63M (+54.7%)
|
-566.55M
est: -478.45M (-18.4%)
|
-877.26M
|
-727.46M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-218.90M
est: -494.17M (+55.7%)
|
-567.93M
est: -436.71M (-30.0%)
|
-885.11M
|
-737.38M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-213.80M
est: -596.80M (+64.2%)
|
-570.28M
est: -430.80M (-32.4%)
|
-846.42M
est: -952.59M (+11.1%)
|
-738.82M
est: -647.68M (-14.1%)
|
-309.08M
-353.54M – -264.62M
+52.3% YoY
|
-269.06M
-357.64M – -180.49M
+12.9% YoY
|
-433.29M
-456.60M – -45.24M
-61.0% YoY
|
-164.79M
-203.97M – -125.59M
+62.0% YoY
|
22.16M
16.89M – 27.43M
+113.4% YoY
|
| SGA |
37.41M
|
130.86M
est: 631.03M (-79.3%)
|
89.24M
|
106.17M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-5.97
est: -7.31 (+18.3%)
|
-12.75
est: -9.79 (-30.3%)
|
-9.28
est: -8.89 (-4.4%)
|
-6.86
est: -6.61 (-3.8%)
|
-3.00
-3.28 – -2.46
+54.7% YoY
|
-2.44
-3.32 – -1.68
+18.5% YoY
|
-2.14
-4.24 – -0.42
+12.4% YoY
|
-1.53
-1.90 – -1.17
+28.5% YoY
|
0.21
0.16 – 0.25
+113.4% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-26 | HC Wainwright & Co. | Neutral | Neutral | Maintain |
| 2026-05-13 | Morgan Stanley | Overweight | Overweight | Maintain |
| 2026-05-05 | RBC Capital | Outperform | Outperform | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-648.40M
OE per share TTM
-6.49
Owner's Yield
-39.90%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
34.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
290
Total invested
1.20B
Insider transactions (90d)
7
Beneficial owners (>5%)
12
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | STATE STREET CORPORATION | 4.59M | 6.74% | — | — | — | — | HC | BOSTON, MASSACHUSETTS | 2023-02-08 | ↗ |
| 2 | Capital International Investors ** | 4.17M | 7.90% | 3.50M | — | 4.17M | — | IA | California | 2020-02-10 | ↗ |
| 3 | (1) BlackRock, Inc. | 4.16M | 6.10% | 4.08M | — | 4.16M | — | HC | Delaware | 2023-02-13 | ↗ |
| 4 | 2 | 4.06M | 5.10% | — | 4.06M | — | — | IN | Delaware | 2023-10-18 | ↗ |
| 5 | Averill Master Fund, Ltd. | 3.84M | 5.60% | — | 3.84M | — | 3.84M | CO | Cayman Islands | 2022-11-02 | ↗ |
| 6 | SSGA FUNDS MANAGEMENT, INC. | 3.54M | 5.19% | — | — | — | — | IA | BOSTON, MASSACHUSETTS | 2023-02-08 | ↗ |
| 7 | John W. Childs | 3.08M | 8.50% | 3.08M | — | 3.08M | — | IN | United States of America | 2017-05-19 | ↗ |
| 8 | Peter Kolchinsky | 2.00M | 5.50% | — | 2.00M | — | 2.00M | IN | Massachusetts | 2018-02-14 | ↗ |
| 9 | RA Capital Management, LLC | 2.00M | 5.50% | — | 2.00M | — | 2.00M | IA | Massachusetts | 2018-02-14 | ↗ |
| 10 | Vivo Capital VIII, LLC | 1.98M | 5.80% | 1.98M | — | 1.98M | — | OO | Delaware | 2017-05-12 | ↗ |
| 11 | 95-1411037 | 13.00 | 9.40% | 6.18M | — | 6.18M | — | IA | Delaware | 2022-02-11 | ↗ |
| 12 | The Capital Group Companies, Inc. | — | 0.00% | 2.33M | — | 2.39M | — | HC | Delaware | 2019-02-08 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
290
-10 vs prev Q
New positions
43
Closed positions
45
Increased
164
Reduced
61
Put/Call ratio
0.26
Calls held
2.05M
Puts held
522.6K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | SUVRETTA CAPITAL MANAGEMENT, LLC | 10.29M +4.7M (+83.0%) | 116.14M +31.8M (+37.7%) | 9.72% +4.232 pp | 2.38% +0.220 pp | USD17.67 -36.1% | 14 qtrs — |
| 2 | STIFEL FINANCIAL CORP | 9.94M +3.3M (+50.3%) | 112.22M +13.0M (+13.1%) | 9.39% +2.936 pp | 0.10% +0.010 pp | USD15.34 -26.4% | 13 qtrs — |
| 3 | BLACKROCK, INC. | 9.45M +1.6M (+20.0%) | 106.67M -11.5M (-9.8%) | 8.93% +1.237 pp | 0.00% 0.000 pp | USD41.04 -72.5% | 6 qtrs — |
| 4 | INFINITUM ASSET MANAGEMENT, LLC | 6.25M +4.6M (+267.6%) | 70.56M +45.0M (+176.5%) | 5.91% +4.246 pp | 10.44% +5.749 pp | USD12.93 -12.7% | 5 qtrs — |
| 5 | STATE STREET CORP | 5.72M +1.5M (+34.2%) | 64.54M +622.3K (+1.0%) | 5.40% +1.243 pp | 0.00% 0.000 pp | USD18.34 -38.4% | 13 qtrs — |
| 6 | TCG CROSSOVER MANAGEMENT, LLC | 4.63M +4.6M (+100.0%) | 52.29M +52.3M (+100.0%) | 4.38% +4.377 pp | 1.73% +1.730 pp | USD11.29 +0.0% | 1 qtrs NEW |
| 7 | VANGUARD GROUP INC | 4.40M +1.5M (+52.9%) | 49.63M +6.5M (+15.0%) | 4.15% +1.346 pp | 0.00% +0.000 pp | USD29.98 -62.3% | 13 qtrs — |
| 8 | D. E. SHAW & CO., INC. | 2.69M +1.4M (+112.7%) | 30.42M +11.4M (+60.0%) | 2.55% +1.309 pp | 0.02% +0.006 pp | USD13.20 -14.5% | 10 qtrs — |
| 9 | FMR LLC | 2.68M +255.3K (+10.5%) | 30.28M -6.1M (-16.9%) | 2.53% +0.164 pp | 0.00% 0.000 pp | USD18.13 -37.7% | 13 qtrs — |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 2.39M +332.1K (+16.1%) | 27.01M -3.9M (-12.7%) | 2.26% +0.248 pp | 0.00% 0.000 pp | USD22.09 -48.9% | 13 qtrs — |
| 11 | BNP PARIBAS ARBITRAGE, SNC | 2.09M +1.3M (+148.2%) | 23.64M +11.0M (+86.7%) | 1.98% +1.155 pp | 0.01% +0.004 pp | USD12.62 -10.5% | 5 qtrs — |
| 12 | PRICE T ROWE ASSOCIATES INC /MD/ | 2.02M +8.9K (+0.4%) | 22.79M -7.4M (-24.4%) | 1.91% -0.055 pp | 0.00% -0.001 pp | USD25.01 -54.9% | 13 qtrs — |
| 13 | GOLDMAN SACHS GROUP INC | 1.96M +383.8K (+24.3%) | 22.15M -1.5M (-6.5%) | 1.85% +0.313 pp | 0.00% 0.000 pp | USD18.15 -37.8% | 13 qtrs — |
| 14 | BANK OF AMERICA CORP /DE/ | 1.79M +1.0M (+127.4%) | 20.24M +8.4M (+71.0%) | 1.69% +0.924 pp | 0.00% +0.001 pp | USD16.67 -32.3% | 13 qtrs — |
| 15 | SCHONFELD STRATEGIC ADVISORS LLC | 1.61M +1.6M (+3,829.9%) | 18.14M +17.5M (+2,855.9%) | 1.52% +1.479 pp | 0.08% +0.077 pp | USD11.38 -0.8% | 9 qtrs — |
| 16 | BALYASNY ASSET MANAGEMENT L.P. | 1.59M +1.2M (+317.7%) | 17.96M +12.2M (+214.2%) | 1.50% +1.132 pp | 0.02% +0.016 pp | USD12.18 -7.3% | 4 qtrs — |
| 17 | QUBE RESEARCH & TECHNOLOGIES LTD | 1.57M +305.0K (+24.1%) | 17.73M -1.3M (-6.7%) | 1.48% +0.248 pp | 0.02% -0.002 pp | USD14.21 -20.5% | 3 qtrs — |
| 18 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 1.50M +850.0K (+130.8%) | 16.94M +7.2M (+73.6%) | 1.42% +0.783 pp | 0.84% +0.181 pp | USD13.88 -18.7% | 4 qtrs — |
| 19 | AQR CAPITAL MANAGEMENT LLC | 1.46M +1.2M (+584.6%) | 16.48M +13.3M (+415.0%) | 1.38% +1.172 pp | 0.01% +0.007 pp | USD12.82 -11.9% | 9 qtrs — |
| 20 | JANUS HENDERSON GROUP PLC | 1.41M -5.4M (-79.2%) | 15.90M -85.8M (-84.4%) | 1.33% -5.285 pp | 0.01% -0.039 pp | USD19.14 -41.0% | 14 qtrs — |
| 21 | CAPITAL RESEARCH GLOBAL INVESTORS | 1.33M +321.3K (+31.8%) | 15.05M -135.8K (-0.9%) | 1.26% +0.272 pp | 0.00% 0.000 pp | USD13.79 -18.1% | 3 qtrs — |
| 22 | MILLENNIUM MANAGEMENT LLC | 1.32M +356.1K (+36.8%) | 14.95M +418.8K (+2.9%) | 1.25% +0.306 pp | 0.01% +0.000 pp | USD17.44 -35.3% | 7 qtrs — |
| 23 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 1.32M +1.2M (+758.4%) | 14.89M +12.6M (+545.6%) | 1.25% +1.096 pp | 0.05% +0.045 pp | USD11.83 -4.6% | 10 qtrs — |
| 24 | CAPTION MANAGEMENT, LLC | 1.30M +532.2K (+69.2%) | 14.69M +3.1M (+27.3%) | 1.23% +0.479 pp | 0.10% +0.011 pp | USD14.76 -23.5% | 11 qtrs — |
| 25 | TWO SIGMA INVESTMENTS, LP | 1.26M +459.4K (+57.5%) | 14.21M +2.2M (+18.4%) | 1.19% +0.409 pp | 0.02% +0.002 pp | USD14.93 -24.4% | 11 qtrs — |
| 26 | MYDA ADVISORS LLC | 1.25M +1.2M (+1,566.7%) | 14.11M +13.0M (+1,153.6%) | 1.18% +1.108 pp | 2.69% +2.444 pp | USD11.51 -1.9% | 2 qtrs — |
| 27 | SIO CAPITAL MANAGEMENT, LLC | 1.24M +1.2M (+100.0%) | 14.05M +14.1M (+100.0%) | 1.18% +1.176 pp | 2.21% +2.211 pp | USD11.29 +0.0% | 1 qtrs NEW |
| 28 | ARS INVESTMENT PARTNERS, LLC | 1.24M +137.1K (+12.4%) | 14.00M -2.6M (-15.4%) | 1.17% +0.095 pp | 0.82% -0.275 pp | USD21.70 -48.0% | 13 qtrs — |
| 29 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 1.19M +1.0M (+614.4%) | 13.46M +11.0M (+437.3%) | 1.13% +0.964 pp | 0.11% +0.080 pp | USD11.78 -4.2% | 3 qtrs — |
| 30 | UBS GROUP AG | 1.19M +68.7K (+6.1%) | 13.42M -3.4M (-20.2%) | 1.12% +0.029 pp | 0.00% -0.001 pp | USD25.53 -55.8% | 13 qtrs — |
| 31 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.16M +22.5K (+2.0%) | 13.15M -4.0M (-23.3%) | 1.10% -0.015 pp | 0.00% 0.000 pp | USD19.85 -43.1% | 13 qtrs — |
| 32 | MORGAN STANLEY | 975.2K +429.4K (+78.7%) | 11.01M +2.8M (+34.4%) | 0.92% +0.388 pp | 0.00% +0.000 pp | USD21.81 -48.2% | 14 qtrs — |
| 33 | IRON TRIANGLE PARTNERS LP | 958.3K +958.3K (+100.0%) | 10.82M +10.8M (+100.0%) | 0.91% +0.906 pp | 1.24% +1.237 pp | USD11.29 +0.0% | 1 qtrs NEW |
| 34 | SIMPLIFY ASSET MANAGEMENT INC. | 958.2K +848.5K (+773.6%) | 10.82M +9.2M (+557.1%) | 0.91% +0.798 pp | 0.18% +0.146 pp | USD11.63 -2.9% | 3 qtrs — |
| 35 | DAFNA CAPITAL MANAGEMENT LLC | 955.2K +720.0K (+306.1%) | 10.78M +7.3M (+205.4%) | 0.90% +0.673 pp | 2.51% +1.633 pp | USD17.17 -34.2% | 14 qtrs — |
| 36 | WALLEYE CAPITAL LLC | 854.4K +783.6K (+1,105.9%) | 9.65M +8.6M (+807.0%) | 0.81% +0.738 pp | 0.03% +0.026 pp | USD11.54 -2.2% | 4 qtrs — |
| 37 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 847.4K +97.7K (+13.0%) | 9.57M -1.7M (-15.0%) | 0.80% +0.069 pp | 0.00% 0.000 pp | USD22.10 -48.9% | 13 qtrs — |
| 38 | NORTHERN TRUST CORP | 840.3K +64.4K (+8.3%) | 9.49M -2.2M (-18.5%) | 0.79% +0.036 pp | 0.00% 0.000 pp | USD22.23 -49.2% | 13 qtrs — |
| 39 | JANE STREET GROUP, LLC | 839.5K +40.2K (+5.0%) | 9.48M -2.5M (-21.0%) | 0.79% +0.013 pp | 0.00% 0.000 pp | USD15.13 -25.4% | 11 qtrs — |
| 40 | ORACLE INVESTMENT MANAGEMENT INC | 772.2K +32.2K (+4.4%) | 8.72M -2.4M (-21.5%) | 0.73% +0.007 pp | 5.19% -1.748 pp | USD68.01 -83.4% | 14 qtrs — |
| 41 | 5AM VENTURE MANAGEMENT, LLC | 739.0K +260.0K (+54.3%) | 8.34M +1.2M (+16.0%) | 0.70% +0.231 pp | 2.62% -0.010 pp | USD30.28 -62.7% | 9 qtrs — |
| 42 | NUVEEN, LLC | 732.0K +355.6K (+94.5%) | 8.26M +2.6M (+46.3%) | 0.69% +0.324 pp | 0.00% +0.001 pp | USD17.85 -36.8% | 4 qtrs — |
| 43 | FIERA CAPITAL CORP | 724.6K +163.2K (+29.1%) | 8.18M -245.7K (-2.9%) | 0.68% +0.136 pp | 0.03% -0.001 pp | USD21.17 -46.7% | 4 qtrs — |
| 44 | KYNAM CAPITAL MANAGEMENT, LP | 702.9K +702.9K (+100.0%) | 7.94M +7.9M (+100.0%) | 0.66% +0.664 pp | 0.51% +0.507 pp | USD11.29 +0.0% | 1 qtrs NEW |
| 45 | ERSTE ASSET MANAGEMENT GMBH | 693.3K +600.0K (+643.1%) | 7.85M +6.5M (+474.0%) | 0.66% +0.564 pp | 0.07% +0.053 pp | USD13.23 -14.7% | 13 qtrs — |
| 46 | ABRDN PLC | 693.5K +693.5K (+100.0%) | 7.83M +7.8M (+100.0%) | 0.66% +0.655 pp | 0.01% +0.012 pp | USD11.29 +0.0% | 1 qtrs NEW |
| 47 | AMERICAN CENTURY COMPANIES INC | 685.6K +19.7K (+3.0%) | 7.74M -2.3M (-22.6%) | 0.65% -0.003 pp | 0.00% -0.001 pp | USD26.18 -56.9% | 13 qtrs — |
| 48 | HRT FINANCIAL LP | 669.1K -112.2K (-14.4%) | 7.55M -4.2M (-35.6%) | 0.63% -0.131 pp | 0.02% -0.019 pp | USD15.17 -25.6% | 4 qtrs — |
| 49 | ANSON FUNDS MANAGEMENT LP | 667.4K +667.4K (+100.0%) | 7.53M +7.5M (+100.0%) | 0.63% +0.631 pp | 0.71% +0.710 pp | USD11.29 +0.0% | 1 qtrs NEW |
| 50 | READYSTATE ASSET MANAGEMENT LP | 651.6K +274.5K (+72.8%) | 7.36M +1.7M (+30.0%) | 0.62% +0.247 pp | 0.30% +0.057 pp | USD12.99 -13.1% | 5 qtrs — |
| 51 | TREXQUANT INVESTMENT LP | 604.2K +404.3K (+202.3%) | 6.82M +3.8M (+127.4%) | 0.57% +0.376 pp | 0.06% +0.030 pp | USD12.37 -8.7% | 12 qtrs — |
| 52 | LMR PARTNERS LLP | 590.8K +574.5K (+3,524.5%) | 6.67M +6.4M (+2,626.3%) | 0.56% +0.542 pp | 0.01% +0.012 pp | USD11.37 -0.7% | 3 qtrs — |
| 53 | JPMORGAN CHASE & CO | 589.6K -745.9K (-55.9%) | 6.66M -13.4M (-66.8%) | 0.56% -0.747 pp | 0.00% -0.001 pp | USD32.44 -65.2% | 13 qtrs — |
| 54 | UBS ASSET MANAGEMENT AMERICAS INC | 574.5K +2.6K (+0.4%) | 6.49M -2.1M (-24.4%) | 0.54% -0.016 pp | 0.00% -0.001 pp | USD38.46 -70.6% | 12 qtrs — |
| 55 | SARISSA CAPITAL MANAGEMENT LP | 513.2K +513.2K (+100.0%) | 5.79M +5.8M (+100.0%) | 0.49% +0.485 pp | 2.60% +2.599 pp | USD11.29 +0.0% | 1 qtrs NEW |
| 56 | PFIZER INC | 505.6K +— (+0.0%) | 5.71M -1.9M (-24.8%) | 0.48% -0.016 pp | 2.41% +0.679 pp | USD37.35 -69.8% | 5 qtrs — |
| 57 | DEEP TRACK CAPITAL, LP | 500.0K +500.0K (+100.0%) | 5.65M +5.6M (+100.0%) | 0.47% +0.473 pp | 0.10% +0.101 pp | USD11.29 +0.0% | 1 qtrs NEW |
| 58 | PERCEPTIVE ADVISORS LLC | 500.0K +500.0K (+100.0%) | 5.65M +5.6M (+100.0%) | 0.47% +0.473 pp | 0.10% +0.101 pp | USD11.29 +0.0% | 1 qtrs NEW |
| 59 | BURKEHILL GLOBAL MANAGEMENT, LP | 500.0K +500.0K (+100.0%) | 5.65M +5.6M (+100.0%) | 0.47% +0.473 pp | 0.37% +0.372 pp | USD11.29 +0.0% | 1 qtrs NEW |
| 60 | RAYMOND JAMES FINANCIAL INC | 436.8K +344.8K (+374.5%) | 4.93M +3.5M (+256.9%) | 0.41% +0.323 pp | 0.00% +0.001 pp | USD13.24 -14.7% | 5 qtrs — |
| 61 | QTR FAMILY WEALTH, LLC | 334.8K +2.5K (+0.8%) | 4.08M -902.7K (-18.1%) | 0.32% -0.008 pp | 1.80% -0.568 pp | USD23.94 -52.8% | 4 qtrs — |
| 62 | TWO SIGMA ADVISERS, LP | 358.7K +145.9K (+68.6%) | 4.05M +855.6K (+26.8%) | 0.34% +0.131 pp | 0.01% +0.002 pp | USD13.50 -16.4% | 9 qtrs — |
| 63 | BARCLAYS PLC | 320.8K +52.8K (+19.7%) | 3.62M -9.8M (-73.0%) | 0.30% +0.041 pp | 0.00% -0.003 pp | USD23.10 -51.1% | 13 qtrs — |
| 64 | WOODLINE PARTNERS LP | 300.4K +— (+0.0%) | 3.39M -1.1M (-24.8%) | 0.28% -0.010 pp | 0.01% -0.008 pp | USD35.32 -68.0% | 13 qtrs — |
| 65 | ALGERT GLOBAL LLC | 293.3K +157.0K (+115.2%) | 3.31M +1.3M (+61.8%) | 0.28% +0.144 pp | 0.05% +0.017 pp | USD13.89 -18.7% | 8 qtrs — |
| 66 | BANK OF NEW YORK MELLON CORP | 272.2K -12.3K (-4.3%) | 3.07M -1.2M (-28.0%) | 0.26% -0.021 pp | 0.00% 0.000 pp | USD22.99 -50.9% | 13 qtrs — |
| 67 | TUDOR INVESTMENT CORP ET AL | 256.6K +256.6K (+100.0%) | 2.90M +2.9M (+100.0%) | 0.24% +0.243 pp | 0.01% +0.005 pp | USD11.29 +0.0% | 1 qtrs NEW |
| 68 | CAPITAL WORLD INVESTORS | 250.0K +— (+0.0%) | 2.82M -930.0K (-24.8%) | 0.24% -0.008 pp | 0.00% 0.000 pp | USD13.88 -18.7% | 13 qtrs — |
| 69 | MASSAR CAPITAL MANAGEMENT, LP | 247.4K +247.4K (+100.0%) | 2.79M +2.8M (+100.0%) | 0.23% +0.234 pp | 0.30% +0.300 pp | USD11.29 +0.0% | 1 qtrs NEW |
| 70 | NEWEDGE WEALTH, LLC | 246.5K -50.0 (0.0%) | 2.78M +726.8K (+35.3%) | 0.23% -0.008 pp | 0.03% +0.002 pp | USD13.69 -17.5% | 12 qtrs — |
| 71 | JUMP FINANCIAL, LLC | 245.9K +225.0K (+1,077.8%) | 2.78M +2.5M (+785.9%) | 0.23% +0.212 pp | 0.03% +0.030 pp | USD11.61 -2.8% | 2 qtrs — |
| 72 | SWISS NATIONAL BANK | 229.2K +60.9K (+36.2%) | 2.59M +61.5K (+2.4%) | 0.22% +0.052 pp | 0.00% +0.000 pp | USD17.71 -36.3% | 12 qtrs — |
| 73 | IKARIAN CAPITAL, LLC | 212.5K +212.5K (+100.0%) | 2.40M +2.4M (+100.0%) | 0.20% +0.201 pp | 0.19% +0.187 pp | USD11.29 +0.0% | 1 qtrs NEW |
| 74 | QUINN OPPORTUNITY PARTNERS LLC | 210.3K +180.3K (+601.1%) | 2.37M +1.9M (+427.3%) | 0.20% +0.170 pp | 0.10% +0.068 pp | USD11.69 -3.4% | 3 qtrs — |
| 75 | RAFFERTY ASSET MANAGEMENT, LLC | 209.3K +45.7K (+28.0%) | 2.36M -92.1K (-3.8%) | 0.20% +0.038 pp | 0.01% +0.000 pp | USD18.40 -38.6% | 13 qtrs — |
| 76 | JAIN GLOBAL LLC | 209.0K +209.0K (+100.0%) | 2.36M +2.4M (+100.0%) | 0.20% +0.198 pp | 0.01% +0.011 pp | USD11.29 +0.0% | 1 qtrs NEW |
| 77 | POINT72 ASSET MANAGEMENT, L.P. | 204.8K +— (+0.0%) | 2.31M -761.9K (-24.8%) | 0.19% -0.007 pp | 0.00% -0.003 pp | USD15.01 -24.8% | 2 qtrs — |
| 78 | DIADEMA PARTNERS LP | 200.0K +200.0K (+100.0%) | 2.26M +2.3M (+100.0%) | 0.19% +0.189 pp | 0.39% +0.389 pp | USD11.29 +0.0% | 5 qtrs — |
| 79 | INVESCO LTD. | 194.8K +72.2K (+59.0%) | 2.20M +359.7K (+19.6%) | 0.18% +0.064 pp | 0.00% +0.000 pp | USD21.20 -46.7% | 13 qtrs — |
| 80 | VOLEON CAPITAL MANAGEMENT LP | 174.0K +174.0K (+100.0%) | 1.96M +2.0M (+100.0%) | 0.16% +0.165 pp | 0.04% +0.042 pp | USD11.29 +0.0% | 1 qtrs NEW |
| 81 | QVT FINANCIAL LP | 170.0K +— (+0.0%) | 1.92M -632.4K (-24.8%) | 0.16% -0.005 pp | 0.16% -0.016 pp | USD26.01 -56.6% | 10 qtrs — |
| 82 | NOMURA HOLDINGS INC | 165.0K +165.0K (+100.0%) | 1.86M +1.9M (+100.0%) | 0.16% +0.156 pp | 0.00% +0.003 pp | USD11.29 +0.0% | 1 qtrs NEW |
| 83 | IEQ CAPITAL, LLC | 163.4K +163.4K (+100.0%) | 1.84M +1.8M (+100.0%) | 0.15% +0.154 pp | 0.01% +0.006 pp | USD11.29 +0.0% | 1 qtrs NEW |
| 84 | NEW YORK STATE COMMON RETIREMENT FUND | 160.3K +— (+0.0%) | 1.81M -596.1K (-24.8%) | 0.15% -0.005 pp | 0.00% -0.001 pp | USD24.43 -53.8% | 13 qtrs — |
| 85 | WELLS FARGO & COMPANY/MN | 151.5K +39.4K (+35.1%) | 1.71M +27.6K (+1.6%) | 0.14% +0.034 pp | 0.00% +0.000 pp | USD22.10 -48.9% | 13 qtrs — |
| 86 | DCF ADVISERS, LLC | 151.5K -20.0K (-11.7%) | 1.71M -863.8K (-33.6%) | 0.14% -0.024 pp | 0.46% -0.368 pp | USD20.06 -43.7% | 7 qtrs — |
| 87 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 150.0K -1.1M (-88.1%) | 1.69M -17.2M (-91.0%) | 0.14% -1.089 pp | 0.00% -0.027 pp | USD19.82 -43.0% | 13 qtrs — |
| 88 | GRAHAM CAPITAL MANAGEMENT, L.P. | 145.9K +112.2K (+333.8%) | 1.65M +1.1M (+226.3%) | 0.14% +0.105 pp | 0.04% +0.031 pp | USD11.94 -5.4% | 3 qtrs — |
| 89 | EVERSEPT PARTNERS, LP | 145.4K +145.4K (+100.0%) | 1.64M +1.6M (+100.0%) | 0.14% +0.137 pp | 0.08% +0.083 pp | USD11.29 +0.0% | 1 qtrs NEW |
| 90 | EMPOWERED FUNDS, LLC | 143.3K -12.5K (-8.0%) | 1.62M -721.0K (-30.8%) | 0.14% -0.017 pp | 0.01% -0.011 pp | USD14.44 -21.8% | 3 qtrs — |
| 91 | TD ASSET MANAGEMENT INC | 141.7K +5.7K (+4.2%) | 1.60M -442.2K (-21.7%) | 0.13% +0.001 pp | 0.00% 0.000 pp | USD27.82 -59.4% | 13 qtrs — |
| 92 | CITADEL ADVISORS LLC | 140.3K +40.2K (+40.2%) | 1.58M +81.5K (+5.4%) | 0.13% +0.035 pp | 0.00% +0.000 pp | USD22.08 -48.9% | 13 qtrs — |
| 93 | TANG CAPITAL MANAGEMENT LLC | 140.0K +— (+0.0%) | 1.58M -520.8K (-24.8%) | 0.13% -0.004 pp | 0.08% -0.003 pp | USD13.88 -18.7% | 13 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
7
Sells
0
Shares acquired
480.9K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+480,851
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-28 | Mehta Kishan | Director | A-Award | A | Stock Options (Right to buy) | 68,693 | 9.61 | 660.1K | 68,693 | D | ↗ |
| 2026-04-28 | Heffernan Michael Thomas | Director | A-Award | A | Stock Options (Right to buy) | 68,693 | 9.61 | 660.1K | 68,693 | D | ↗ |
| 2026-04-28 | HUGIN ROBERT J | Director | A-Award | A | Stock Options (Right to buy) | 68,693 | 9.61 | 660.1K | 68,693 | D | ↗ |
| 2026-04-28 | GREGORY JULIA P | Director | A-Award | A | Stock Options (Right to buy) | 68,693 | 9.61 | 660.1K | 68,693 | D | ↗ |
| 2026-04-28 | CHILDS JOHN W | Director | A-Award | A | Stock Options (Right to buy) | 68,693 | 9.61 | 660.1K | 68,693 | D | ↗ |
| 2026-04-28 | Bailey Gregory | Director | A-Award | A | Stock Options (Right to buy) | 68,693 | 9.61 | 660.1K | 68,693 | D | ↗ |
| 2026-04-28 | Antonijevic Irina | Director | A-Award | A | Stock Options (Right to buy) | 68,693 | 9.61 | 660.1K | 68,693 | D | ↗ |
| 2026-03-17 | Mehta Kishan | Director | G-Gift | A | Common Shares | 17,342 | 0.00 | — | 17,342 | I | ↗ |
| 2026-02-27 | Gentile Kimberly | Officer | A-Award | A | Stock Options (Right to buy) | 175,000 | 11.52 | 2.02M | 175,000 | D | ↗ |
| 2026-02-27 | Coric Vlad | Director / Officer | A-Award | A | Stock Options (Right to buy) | 550,000 | 11.52 | 6.34M | 550,000 | D | ↗ |
| 2026-02-27 | Clark George C. | Officer | A-Award | A | Stock Options (Right to buy) | 50,000 | 11.52 | 576.0K | 50,000 | D | ↗ |
| 2026-02-27 | Car Bruce | Officer | A-Award | A | Stock Options (Right to buy) | 175,000 | 11.52 | 2.02M | 175,000 | D | ↗ |
| 2026-02-27 | Buten Matthew | Officer | A-Award | A | Stock Options (Right to buy) | 175,000 | 11.52 | 2.02M | 175,000 | D | ↗ |
| 2026-01-05 | Gentile Kimberly | Officer | M-Exempt | D | Restricted Share Unit Award | 3,750 | 0.00 | — | 7,500 | D | ↗ |
| 2026-01-05 | Coric Vlad | Director / Officer | M-Exempt | A | Common Shares | 14,250 | 0.00 | — | 1,811,398 | D | ↗ |
| 2026-01-05 | Clark George C. | Officer | M-Exempt | D | Restricted Share Unit Award | 2,500 | 0.00 | — | 5,000 | D | ↗ |
| 2026-01-05 | Car Bruce | Officer | F-InKind | D | Common Shares | 2,381 | 9.93 | 23.6K | 7,715 | D | ↗ |
| 2026-01-05 | Buten Matthew | Officer | M-Exempt | D | Restricted Share Unit Award | 4,250 | 0.00 | — | 8,500 | D | ↗ |
| 2025-11-17 | Clark George C. | Officer | P-Purchase | A | Common Shares | 17,000 | 8.52 | 144.8K | 20,000 | I | ↗ |
| 2025-11-13 | Coric Vlad | Director / Officer | P-Purchase | A | Common Shares | 333,333 | 7.50 | 2.50M | 1,195,275 | I | ↗ |
| 2025-11-13 | CHILDS JOHN W | Director | P-Purchase | A | Common Shares | 3,333,333 | 7.50 | 25.00M | 5,653,904 | I | ↗ |
| 2025-11-13 | Bailey Gregory | Director | P-Purchase | A | Common Shares | 400,000 | 7.50 | 3.00M | 2,020,071 | D | ↗ |
| 2025-05-05 | Mehta Kishan | Director | A-Award | A | Stock Options (Right to buy) | 31,716 | 22.62 | 717.4K | 31,716 | D | ↗ |
| 2025-05-05 | Heffernan Michael Thomas | Director | A-Award | A | Stock Options (Right to buy) | 31,716 | 22.62 | 717.4K | 31,716 | D | ↗ |
| 2025-05-05 | HUGIN ROBERT J | Director | A-Award | A | Stock Options (Right to buy) | 31,716 | 22.62 | 717.4K | 31,716 | D | ↗ |
| 2025-05-05 | GREGORY JULIA P | Director | A-Award | A | Stock Options (Right to buy) | 31,716 | 22.62 | 717.4K | 31,716 | D | ↗ |
| 2025-05-05 | CHILDS JOHN W | Director | A-Award | A | Stock Options (Right to buy) | 31,716 | 22.62 | 717.4K | 31,716 | D | ↗ |
| 2025-05-05 | Bailey Gregory | Director | A-Award | A | Stock Options (Right to buy) | 31,716 | 22.62 | 717.4K | 31,716 | D | ↗ |
| 2025-05-05 | Antonijevic Irina | Director | A-Award | A | Stock Options (Right to buy) | 31,716 | 22.62 | 717.4K | 31,716 | D | ↗ |
| 2025-03-04 | CHILDS JOHN W | Director | P-Purchase | A | Common Shares | 28,400 | 30.43 | 864.1K | 2,323,971 | I | ↗ |
| 2025-01-05 | Gentile Kimberly | Officer | M-Exempt | D | Restricted Share Unit Award | 3,750 | 0.00 | — | 11,250 | D | ↗ |
| 2025-01-05 | Coric Vlad | Director / Officer | A-Award | A | Stock Options (Right to buy) | 343,000 | 38.64 | 13.25M | 343,000 | D | ↗ |
| 2025-01-05 | Clark George C. | Officer | M-Exempt | D | Restricted Share Unit Award | 2,500 | 0.00 | — | 7,500 | D | ↗ |
| 2025-01-05 | Car Bruce | Officer | F-InKind | D | Common Shares | 2,331 | 38.64 | 90.1K | 4,802 | D | ↗ |
| 2025-01-05 | Buten Matthew | Officer | M-Exempt | D | Restricted Share Unit Award | 4,250 | 0.00 | — | 12,750 | D | ↗ |
| 2024-12-30 | CHILDS JOHN W | Director | P-Purchase | A | Common Shares | 29,000 | 35.94 | 1.04M | 2,368,741 | I | ↗ |
| 2024-10-02 | Coric Vlad | Director / Officer | P-Purchase | A | Common Shares | 21,052 | 47.50 | 1,000.0K | 861,942 | I | ↗ |
| 2024-10-02 | CHILDS JOHN W | Director | P-Purchase | A | Common Shares | 21,052 | 47.50 | 1,000.0K | 21,052 | I | ↗ |
| 2024-09-24 | Bailey Gregory | Director | P-Purchase | A | Common Shares | 5,000 | 44.19 | 221.0K | 1,620,071 | D | ↗ |
| 2024-07-18 | CHILDS JOHN W | Director | P-Purchase | A | Common Shares | 28,400 | 35.67 | 1.01M | 2,339,741 | — | ↗ |
| 2024-06-17 | Car Bruce | Officer | P-Purchase | A | Common Shares | 30,000 | 33.58 | 1.01M | 30,000 | — | ↗ |
| 2024-05-30 | CHILDS JOHN W | Director | P-Purchase | A | Common Shares | 28,000 | 35.58 | 996.2K | 2,311,341 | — | ↗ |
| 2024-05-13 | CHILDS JOHN W | Director | P-Purchase | A | Common Shares | 28,500 | 35.17 | 1.00M | 2,283,341 | — | ↗ |
| 2024-05-13 | Bailey Gregory | Director | P-Purchase | A | Common Shares | 15,000 | 34.19 | 512.9K | 1,615,071 | — | ↗ |
| 2024-04-30 | Mehta Kishan | Director | A-Award | A | Stock Option (Right to Buy) | 16,592 | 38.80 | 643.8K | 16,592 | — | ↗ |
| 2024-04-30 | Heffernan Michael Thomas | Director | A-Award | A | Stock Option (Right to Buy) | 16,592 | 38.80 | 643.8K | 16,592 | — | ↗ |
| 2024-04-30 | HUGIN ROBERT J | Director | A-Award | A | Stock Option (Right to Buy) | 16,592 | 38.80 | 643.8K | 16,592 | — | ↗ |
| 2024-04-30 | GREGORY JULIA P | Director | A-Award | A | Stock Option (Right to Buy) | 16,592 | 38.80 | 643.8K | 16,592 | — | ↗ |
| 2024-04-30 | CHILDS JOHN W | Director | A-Award | A | Stock Option (Right to Buy) | 16,592 | 38.80 | 643.8K | 16,592 | — | ↗ |
| 2024-04-30 | Bailey Gregory | Director | A-Award | A | Stock Option (Right to Buy) | 16,592 | 38.80 | 643.8K | 16,592 | — | ↗ |
| 2024-04-30 | Antonijevic Irina | Director | A-Award | A | Stock Option (Right to Buy) | 16,592 | 38.80 | 643.8K | 16,592 | — | ↗ |
| 2024-04-24 | Bailey Gregory | Director | P-Purchase | A | Common Shares | 25,503 | 39.18 | 999.2K | 1,600,071 | — | ↗ |
| 2024-04-22 | Coric Vlad | Director / Officer | P-Purchase | A | Common Shares | 121,951 | 41.00 | 5.00M | 1,788,417 | — | ↗ |
| 2024-04-22 | CHILDS JOHN W | Director | P-Purchase | A | Common Shares | 73,170 | 41.00 | 3.00M | 2,254,841 | — | ↗ |
| 2024-04-22 | Bailey Gregory | Director | P-Purchase | A | Common Shares | 48,780 | 41.00 | 2.00M | 1,574,568 | — | ↗ |
| 2024-04-05 | Coric Vlad | Director / Officer | A-Award | A | Common Shares | 232 | 0.00 | — | 1,666,466 | — | ↗ |
| 2024-04-05 | CHILDS JOHN W | Director | A-Award | A | Common Shares | 2,091 | 0.00 | — | 2,181,671 | — | ↗ |
| 2024-03-08 | Coric Vlad | Director / Officer | A-Award | A | Common Shares | 2,162 | 0.00 | — | 1,666,234 | — | ↗ |
| 2024-03-08 | CHILDS JOHN W | Director | A-Award | A | Common Shares | 19,412 | 0.00 | — | 2,179,580 | — | ↗ |
| 2024-01-08 | Coric Vlad | Director / Officer | A-Award | A | Common Shares | 5,400 | 0.00 | — | 1,662,431 | — | ↗ |
| 2024-01-08 | CHILDS JOHN W | Director | J-Other | A | Common Shares | 48,505 | 0.00 | — | 2,160,168 | — | ↗ |
| 2024-01-02 | Gentile Kimberly | Officer | A-Award | A | Stock Options (Right to buy) | 96,250 | 41.93 | 4.04M | 96,250 | — | ↗ |
| 2024-01-02 | Coric Vlad | Director / Officer | A-Award | A | Stock Options (Right to buy) | 275,000 | 41.93 | 11.53M | 275,000 | — | ↗ |
| 2024-01-02 | Clark George C. | Officer | A-Award | A | Stock Options (Right to buy) | 27,500 | 41.93 | 1.15M | 27,500 | — | ↗ |
| 2024-01-02 | Car Bruce | Officer | A-Award | A | Stock Options (Right to buy) | 96,250 | 41.93 | 4.04M | 96,250 | — | ↗ |
| 2024-01-02 | Buten Matthew | Officer | A-Award | A | Stock Options (Right to buy) | 96,250 | 41.93 | 4.04M | 96,250 | — | ↗ |
| 2023-12-29 | Antonijevic Irina | Director | M-Exempt | D | Stock Options (Right to Buy) | 11,000 | 7.00 | 77.0K | 114,000 | — | ↗ |
| 2023-11-02 | Gentile Kimberly | Officer | A-Award | A | Stock Options (Right to buy) | 78,750 | 29.49 | 2.32M | 78,750 | — | ↗ |
| 2023-11-02 | Coric Vlad | Director / Officer | A-Award | A | Stock Options (Right to buy) | 225,000 | 29.49 | 6.64M | 225,000 | — | ↗ |
| 2023-11-02 | Clark George C. | Officer | A-Award | A | Stock Options (Right to buy) | 22,500 | 29.49 | 663.5K | 22,500 | — | ↗ |
| 2023-11-02 | Car Bruce | Officer | A-Award | A | Stock Options (Right to buy) | 78,750 | 29.49 | 2.32M | 78,750 | — | ↗ |
| 2023-11-02 | Buten Matthew | Officer | A-Award | A | Stock Options (Right to buy) | 78,750 | 29.49 | 2.32M | 78,750 | — | ↗ |
| 2023-10-05 | Coric Vlad | Director / Officer | P-Purchase | A | Common Shares | 113,637 | 22.00 | 2.50M | 1,657,031 | — | ↗ |
| 2023-10-05 | CHILDS JOHN W | Director | P-Purchase | A | Common Shares | 318,000 | 22.00 | 7.00M | 3,998,952 | — | ↗ |
| 2023-10-05 | Buten Matthew | Officer | P-Purchase | A | Common Shares | 22,727 | 22.00 | 500.0K | 189,380 | — | ↗ |
| 2023-10-04 | Bailey Gregory | Director | P-Purchase | A | Common Shares | 17,817 | 22.57 | 402.1K | 1,525,788 | — | ↗ |
| 2023-08-30 | CHILDS JOHN W | Director | P-Purchase | A | Common Shares | 50,000 | 18.44 | 922.2K | 1,975,118 | — | ↗ |
| 2023-08-04 | CHILDS JOHN W | Director | P-Purchase | A | Common Shares | 100,000 | 19.78 | 1.98M | 1,925,118 | — | ↗ |
| 2023-05-02 | Mehta Kishan | Director | A-Award | A | Stock Option (Right to Buy) | 52,906 | 13.20 | 698.4K | 52,906 | — | ↗ |
| 2023-05-02 | Heffernan Michael Thomas | Director | A-Award | A | Stock Option (Right to Buy) | 52,906 | 13.20 | 698.4K | 52,906 | — | ↗ |
| 2023-05-02 | HUGIN ROBERT J | Director | A-Award | A | Stock Option (Right to Buy) | 52,906 | 13.20 | 698.4K | 52,906 | — | ↗ |
| 2023-05-02 | GREGORY JULIA P | Director | A-Award | A | Stock Option (Right to Buy) | 52,906 | 13.20 | 698.4K | 52,906 | — | ↗ |
| 2023-05-02 | CHILDS JOHN W | Director | A-Award | A | Stock Option (Right to Buy) | 52,906 | 13.20 | 698.4K | 52,906 | — | ↗ |
| 2023-05-02 | Bailey Gregory | Director | A-Award | A | Stock Option (Right to Buy) | 52,906 | 13.20 | 698.4K | 52,906 | — | ↗ |
| 2023-05-02 | Antonijevic Irina | Director | A-Award | A | Stock Option (Right to Buy) | 52,906 | 13.20 | 698.4K | 52,906 | — | ↗ |
| 2022-11-08 | Clark George C. | Director / Officer | — | D | Stock Options (Right to buy) | 185,715 | 7.00 | 1.30M | — | — | ↗ |
| 2022-10-31 | Coric Vlad | Director / Officer | P-Purchase | A | Common Stock | 25,800 | 15.97 | 412.0K | 1,543,394 | — | ↗ |
| 2022-10-28 | Coric Vlad | Director / Officer | P-Purchase | A | Common Shares | 41,930 | 14.87 | 623.4K | 1,517,594 | — | ↗ |
| 2022-10-25 | GREGORY JULIA P | Director | P-Purchase | A | Common Shares | 9,523 | 10.50 | 100.0K | 25,665 | — | ↗ |
| 2022-10-25 | Coric Vlad | Director / Officer | P-Purchase | A | Common Shares | 853,380 | 10.50 | 8.96M | 1,475,664 | — | ↗ |
| 2022-10-25 | CHILDS JOHN W | Director | P-Purchase | A | Common Shares | 1,328,867 | 10.50 | 13.95M | 1,825,118 | — | ↗ |
| 2022-10-25 | Buten Matthew | Director / Officer | P-Purchase | A | Common Shares | 142,857 | 10.50 | 1.50M | 166,653 | — | ↗ |
| 2022-10-25 | Bailey Gregory | Director | P-Purchase | A | Common Shares | 200,000 | 10.50 | 2.10M | 1,507,971 | — | ↗ |
| 2022-10-05 | Coric Vlad | Director / Officer | P-Purchase | A | Common Shares | 52,523 | 11.79 | 619.2K | 397,343 | — | ↗ |
| 2022-10-05 | CHILDS JOHN W | Director | P-Purchase | A | Common Shares | 32,841 | 9.70 | 318.4K | 1,791,251 | — | ↗ |
| 2022-10-03 | Tilton John | Director / Officer | D-Return | D | Common Shares | 5,068 | 148.50 | 752.6K | 1,614 | — | ↗ |
| 2022-10-03 | Stock Elyse | Director / Officer | D-Return | D | Stock Options (Right to Buy) | 775 | 0.00 | — | 0 | — | ↗ |
| 2022-10-03 | Mehta Kishan | Director | D-Return | D | Stock Options (Right to Buy) | 20,000 | 0.00 | — | 0 | — | ↗ |
| 2022-10-03 | JONES WILLIAM A JR | Director | D-Return | D | Restricted Share Unit Award | 3,000 | 0.00 | — | 0 | — | ↗ |
| 2022-10-03 | Heffernan Michael Thomas | Director | D-Return | D | Stock Options (Right to Buy) | 26,200 | 0.00 | — | 0 | — | ↗ |
| 2022-10-03 | HUGIN ROBERT J | Director | D-Return | D | Restricted Share Unit Award | 3,417 | 0.00 | — | 0 | — | ↗ |
| 2022-10-03 | Gentile Kimberly | Director | D-Return | D | Restricted Share Unit Award | 13,000 | 0.00 | — | 0 | — | ↗ |
| 2022-10-03 | GREGORY JULIA P | Director | D-Return | D | Stock Options (Right to Buy) | 18,000 | 0.00 | — | 0 | — | ↗ |
| 2022-10-03 | Engelhart James | Director | D-Return | D | Stock Options (Right to Buy) | 27,602 | 0.00 | — | 0 | — | ↗ |
| 2022-10-03 | Coric Vlad | Director / Officer | J-Other | A | Common Shares | 461,470 | 0.00 | — | 461,470 | — | ↗ |
| 2022-10-03 | Conway Charles | Director / Officer | D-Return | D | Stock Options (Right to Buy) | 41,432 | 0.00 | — | 0 | — | ↗ |
| 2022-10-03 | Clark George C. | Director / Officer | D-Return | D | Common Shares | 4,292 | 148.50 | 637.4K | 0 | — | ↗ |
| 2022-10-03 | Car Bruce | Officer | A-Award | A | Stock Options (Right to Buy) | 300,000 | 7.00 | 2.10M | 300,000 | — | ↗ |
| 2022-10-03 | CHILDS JOHN W | Director | D-Return | D | Stock Options (Right to Buy) | 8,239 | 0.00 | — | 0 | — | ↗ |
| 2022-10-03 | Buten Matthew | Director / Officer | D-Return | D | Restricted Share Unit Award | 37,500 | 0.00 | — | 0 | — | ↗ |
| 2022-10-03 | Bailey Gregory | Director | M-Exempt | A | Common Shares | 4,119 | 4.84 | 19.9K | 1,295,948 | — | ↗ |
| 2022-10-03 | Antonijevic Irina | Director | D-Return | D | Restricted Share Unit Award | 5,070 | 0.00 | — | 0 | — | ↗ |
| 2022-09-28 | HUGIN ROBERT J | Director | — | D | No Securities Owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-09-28 | Car Bruce | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-09-28 | CHILDS JOHN W | Director | — | D | No Securities Owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-09-28 | Bailey Gregory | Director | — | D | No Securities Owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-09-22 | Coric Vlad | Director / Officer | — | D | No Securities Owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-08-19 | Bailey Gregory | Director | P-Purchase | A | Common Stock | 38,000 | 148.04 | 5.63M | 2,583,658 | — | ↗ |
| 2022-05-11 | Antonijevic Irina | Director | A-Award | A | Restricted Share Unit Award | 5,070 | 0.00 | — | 5,070 | — | ↗ |
| 2022-05-10 | Clark George C. | Director / Officer | S-Sale | D | Common Shares | 4,200 | 141.50 | 594.3K | 4,065 | — | ↗ |
| 2022-05-01 | Antonijevic Irina | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-04-28 | Mehta Kishan | Director | A-Award | A | Stock Option (Right to Buy) | 8,239 | 0.00 | — | 8,239 | — | ↗ |
| 2022-04-28 | Heffernan Michael Thomas | Director | A-Award | A | Stock Option (Right to Buy) | 8,239 | 0.00 | — | 8,239 | — | ↗ |
| 2022-04-28 | HUGIN ROBERT J | Director | A-Award | A | Stock Option (Right to Buy) | 8,239 | 0.00 | — | 8,239 | — | ↗ |
| 2022-04-28 | GREGORY JULIA P | Director | A-Award | A | Stock Option (Right to Buy) | 8,239 | 0.00 | — | 8,239 | — | ↗ |
| 2022-04-28 | CHILDS JOHN W | Director | A-Award | A | Stock Option (Right to Buy) | 8,239 | 97.74 | 805.3K | 8,239 | — | ↗ |
| 2022-04-28 | Bailey Gregory | Director | A-Award | A | Stock Option (Right to Buy) | 8,239 | 0.00 | — | 8,239 | — | ↗ |
| 2022-01-19 | Clark George C. | Officer | M-Exempt | A | Common Shares | 1,920 | 32.42 | 62.2K | 15,390 | — | ↗ |
| 2022-01-10 | Stock Elyse | Officer | M-Exempt | A | Common Shares | 937 | 0.00 | — | 5,374 | — | ↗ |
| 2022-01-10 | Mehta Kishan | Director | M-Exempt | D | Restricted Share Unit Award | 1,875 | 0.00 | — | 1,875 | — | ↗ |
| 2022-01-10 | Clark George C. | Officer | M-Exempt | D | Restricted Share Unit Award | 1,000 | 0.00 | — | 1,000 | — | ↗ |
| 2022-01-07 | Tilton John | Officer | M-Exempt | D | Restricted Share Unit Award | 875 | 0.00 | — | 2,625 | — | ↗ |
| 2022-01-07 | Stock Elyse | Officer | M-Exempt | D | Restricted Share Unit Award | 3,250 | 0.00 | — | 9,750 | — | ↗ |
| 2022-01-07 | JONES WILLIAM A JR | Officer | F-InKind | D | Common Shares | 1,631 | 128.87 | 210.2K | 13,999 | — | ↗ |
| 2022-01-07 | Gentile Kimberly | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 26,000 | 128.87 | 3.35M | 26,000 | — | ↗ |
| 2022-01-07 | Engelhart James | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 26,000 | 128.87 | 3.35M | 26,000 | — | ↗ |
| 2022-01-07 | Coric Vlad | Director / Officer | F-InKind | D | Common Shares | 4,634 | 128.87 | 597.2K | 37,584 | — | ↗ |
| 2022-01-07 | Conway Charles | Officer | A-Award | A | Restricted Share Unit Award | 11,500 | 0.00 | — | 11,500 | — | ↗ |
| 2022-01-07 | Clark George C. | Officer | M-Exempt | A | Common Shares | 1,000 | 0.00 | — | 9,706 | — | ↗ |
| 2022-01-07 | Buten Matthew | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 26,000 | 128.87 | 3.35M | 26,000 | — | ↗ |
| 2022-01-06 | Tilton John | Officer | M-Exempt | A | Common Shares | 1,250 | 0.00 | — | 4,955 | — | ↗ |
| 2022-01-06 | Stock Elyse | Officer | M-Exempt | A | Common Shares | 1,250 | 0.00 | — | 3,437 | — | ↗ |
| 2022-01-06 | JONES WILLIAM A JR | Officer | F-InKind | D | Common Shares | 2,230 | 123.86 | 276.2K | 11,880 | — | ↗ |
| 2022-01-06 | Gentile Kimberly | Officer | F-InKind | D | Common Shares | 1,800 | 123.86 | 222.9K | 11,653 | — | ↗ |
| 2022-01-06 | Engelhart James | Officer | M-Exempt | A | Common Shares | 3,750 | 0.00 | — | 15,234 | — | ↗ |
| 2022-01-06 | Coric Vlad | Director / Officer | F-InKind | D | Common Shares | 5,854 | 123.86 | 725.1K | 32,218 | — | ↗ |
| 2022-01-06 | Conway Charles | Officer | F-InKind | D | Common Shares | 1,800 | 123.86 | 222.9K | 22,135 | — | ↗ |
| 2022-01-06 | Clark George C. | Officer | M-Exempt | A | Common Shares | 875 | 0.00 | — | 9,115 | — | ↗ |
| 2021-12-31 | Doogan Declan | Director | — | I | Common Shares | 0 | 0.00 | — | 676,002 | — | ↗ |
| 2021-12-31 | Coric Vlad | Director / Officer | — | I | Common Shares | 0 | 0.00 | — | 19,130 | — | ↗ |
| 2021-12-31 | Buten Matthew | Officer | M-Exempt | D | Restricted Share Unit Award | 12,500 | 0.00 | — | 37,500 | — | ↗ |
| 2021-12-20 | Heffernan Michael Thomas | Director | A-Award | A | Restricted Share Unit Award | 3,320 | 0.00 | — | 3,320 | — | ↗ |
| 2021-12-20 | HUGIN ROBERT J | Director | A-Award | A | Restricted Share Unit Award | 3,417 | 0.00 | — | 3,417 | — | ↗ |
| 2021-12-20 | GREGORY JULIA P | Director | M-Exempt | A | Common Shares | 12,000 | 23.63 | 283.6K | 12,000 | — | ↗ |
| 2021-12-20 | Clark George C. | Officer | S-Sale | D | Common Shares | 1,915 | 123.84 | 237.2K | 8,240 | — | ↗ |
| 2021-12-15 | Stock Elyse | Officer | M-Exempt | A | Common Shares | 14,923 | 10.82 | 161.5K | 29,386 | — | ↗ |
| 2021-12-14 | Stock Elyse | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 3,362 | 20.79 | 69.9K | 18,534 | — | ↗ |
| 2021-12-10 | Engelhart James | Officer | M-Exempt | A | Common Shares | 35,000 | 0.00 | — | 46,196 | — | ↗ |
| 2021-12-08 | Buten Matthew | Officer | A-Award | A | Restricted Share Unit Award | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2021-11-29 | Doogan Declan | Director | S-Sale | D | Common Shares | 13,026 | 112.40 | 1.46M | 882,147 | — | ↗ |
| 2021-11-26 | Clark George C. | Officer | M-Exempt | D | Restricted Share Unit Award | 5,000 | 0.00 | — | 15,000 | — | ↗ |
| 2021-11-25 | Tilton John | Officer | M-Exempt | D | Restricted Share Unit Award | 1,250 | 0.00 | — | 1,250 | — | ↗ |
| 2021-11-25 | Stock Elyse | Officer | M-Exempt | A | Common Shares | 3,375 | 0.00 | — | 9,066 | — | ↗ |
| 2021-11-25 | JONES WILLIAM A JR | Officer | M-Exempt | D | Restricted Share Unit Award | 3,000 | 0.00 | — | 3,000 | — | ↗ |
| 2021-11-25 | Gentile Kimberly | Officer | M-Exempt | D | Restricted Share Unit Award | 3,750 | 0.00 | — | 3,750 | — | ↗ |
| 2021-11-25 | Engelhart James | Officer | M-Exempt | A | Common Shares | 3,700 | 0.00 | — | 12,911 | — | ↗ |
| 2021-11-25 | Coric Vlad | Director / Officer | M-Exempt | D | Restricted Share Unit Award | 10,950 | 0.00 | — | 10,950 | — | ↗ |
| 2021-11-25 | Conway Charles | Officer | M-Exempt | D | Restricted Share Unit Award | 3,000 | 0.00 | — | 3,000 | — | ↗ |
| 2021-11-23 | Conway Charles | Officer | M-Exempt | A | Common Shares | 885 | 20.79 | 18.4K | 16,897 | — | ↗ |
| 2021-11-23 | Clark George C. | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 1,915 | 32.42 | 62.1K | 4,795 | — | ↗ |
| 2021-11-16 | Doogan Declan | Director | M-Exempt | A | Common Shares | 30,000 | 10.82 | 324.6K | 914,913 | — | ↗ |
| 2021-11-15 | CHILDS JOHN W | Director | M-Exempt | D | Stock Option (Right to Buy) | 37,700 | 9.29 | 350.2K | 0 | — | ↗ |
| 2021-11-10 | CHILDS JOHN W | Director | P-Purchase | A | Common Shares | 3,890 | 122.75 | 477.5K | 2,549,691 | — | ↗ |
| 2021-08-06 | Clark George C. | Officer | — | D | Common Shares | 0 | 0.00 | — | 5,558 | — | ↗ |
| 2021-06-15 | Mehta Kishan | Director | A-Award | A | Stock Options (Right to buy) | 13,004 | 93.21 | 1.21M | 13,004 | — | ↗ |
| 2021-05-05 | Heffernan Michael Thomas | Director | A-Award | A | Stock Option (Right to Buy) | 11,996 | 71.94 | 863.0K | 11,996 | — | ↗ |
| 2021-05-05 | HUGIN ROBERT J | Director | A-Award | A | Stock Option (Right to Buy) | 11,996 | 71.94 | 863.0K | 11,996 | — | ↗ |
| 2021-05-05 | GREGORY JULIA P | Director | A-Award | A | Stock Option (Right to Buy) | 11,996 | 71.94 | 863.0K | 11,996 | — | ↗ |
| 2021-05-05 | Doogan Declan | Director | A-Award | A | Stock Option (Right to Buy) | 11,996 | 71.94 | 863.0K | 11,996 | — | ↗ |
| 2021-05-05 | CHILDS JOHN W | Director | A-Award | A | Stock Option (Right to Buy) | 11,996 | 71.94 | 863.0K | 11,996 | — | ↗ |
| 2021-05-05 | Bailey Gregory | Director | A-Award | A | Stock Option (Right to Buy) | 11,996 | 71.94 | 863.0K | 11,996 | — | ↗ |
| 2021-03-17 | CHILDS JOHN W | Director | P-Purchase | A | Common Shares | 13,157 | 76.00 | 999.9K | 2,545,801 | — | ↗ |
| 2021-03-02 | CHILDS JOHN W | Director | P-Purchase | A | Common Shares | 10,000 | 85.14 | 851.4K | 2,532,644 | — | ↗ |
| 2021-01-25 | CHILDS JOHN W | Director | J-Other | A | Common Shares | 5,706 | 0.00 | — | 2,522,644 | — | ↗ |
| 2021-01-06 | Tilton John | Officer | M-Exempt | A | Common Shares | 1,250 | 0.00 | — | 3,151 | — | ↗ |
| 2021-01-06 | Stock Elyse | Officer | M-Exempt | A | Common Shares | 1,250 | 0.00 | — | 2,187 | — | ↗ |
| 2021-01-06 | JONES WILLIAM A JR | Officer | A-Award | A | Restricted Share Unit Award | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2021-01-06 | Gentile Kimberly | Officer | A-Award | A | Restricted Share Unit Award | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2021-01-06 | Engelhart James | Officer | A-Award | A | Employee Stock Option (right to buy) | 30,000 | 83.38 | 2.50M | 30,000 | — | ↗ |
| 2021-01-06 | Coric Vlad | Director / Officer | F-InKind | D | Common Shares | 5,802 | 83.38 | 483.8K | 19,409 | — | ↗ |
| 2021-01-06 | Conway Charles | Officer | A-Award | A | Employee Stock Option (right to buy) | 30,000 | 83.38 | 2.50M | 30,000 | — | ↗ |
| 2020-12-31 | Coric Vlad | Director / Officer | — | I | Common Shares | 0 | 0.00 | — | 100,000 | — | ↗ |
| 2020-12-31 | Conway Charles | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-11-25 | Tilton John | Officer | M-Exempt | D | Restricted Share Unit Award | 1,250 | 0.00 | — | 2,500 | — | ↗ |
| 2020-11-25 | Stock Elyse | Officer | M-Exempt | D | Restricted Share Unit Award | 3,375 | 0.00 | — | 6,750 | — | ↗ |
| 2020-11-25 | JONES WILLIAM A JR | Officer | M-Exempt | D | Restricted Share Unit Award | 3,000 | 0.00 | — | 6,000 | — | ↗ |
| 2020-11-25 | Gentile Kimberly | Officer | M-Exempt | D | Restricted Share Unit Award | 3,750 | 0.00 | — | 7,500 | — | ↗ |
| 2020-11-25 | Engelhart James | Officer | M-Exempt | A | Common Shares | 3,700 | 0.00 | — | 8,222 | — | ↗ |
| 2020-11-25 | Coric Vlad | Director / Officer | M-Exempt | D | Restricted Share Unit Award | 10,950 | 0.00 | — | 21,900 | — | ↗ |
| 2020-11-25 | Conway Charles | Officer | M-Exempt | A | Common Shares | 3,000 | 0.00 | — | 8,639 | — | ↗ |
Executive team
Top executives
Shares Outstanding
105.87M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Vlad Coric, M.D. Chief Executive Officer | 920.4K | 460.2K | 2.20M | 9.90M | — | 17.3K | 13.50M | 89.65% | ↗ |
| 2 | 2025 | Bruce Car, Ph.D. Chief Scientific Officer | 536.2K | 241.3K | 734.2K | 3.23M | — | 23.9K | 4.77M | 83.19% | ↗ |
| 3 | 2025 | Matthew Buten Chief Financial Officer | 596.2K | 238.5K | 656.9K | 3.00M | — | 23.9K | 4.52M | 80.99% | ↗ |
| 4 | 2025 | Kimberly Gentile Senior Vice President, Clinical Operations | 508.9K | 229.0K | 579.6K | 2.63M | — | 19.8K | 3.96M | 80.88% | ↗ |
| 5 | 2024 | Vlad Coric, M.D. Chief Executive Officer | 885.0K | 1.16M | — | 8.42M | — | 16.8K | 10.48M | 80.31% | ↗ |
| 6 | 2024 | Matthew Buten Chief Financial Officer | 573.3K | 501.6K | — | 2.95M | — | 22.9K | 4.04M | 72.85% | ↗ |
| 7 | 2024 | Bruce Car, Ph.D. Chief Scientific Officer | 515.6K | 451.1K | — | 2.95M | — | 22.9K | 3.94M | 74.85% | ↗ |
| 8 | 2024 | Kimberly Gentile Senior Vice President, Clinical Operations | 489.3K | 385.3K | — | 2.95M | — | 18.9K | 3.84M | 76.73% | ↗ |
| 9 | 2023 | Vlad Coric, M.D. Chief Executive Officer | 840.0K | 1.10M | — | 4.86M | — | 16.1K | 6.82M | 71.28% | ↗ |
| 10 | 2023 | Matthew Buten Chief Financial Officer | 551.3K | 482.4K | — | 1.70M | — | 20.8K | 2.76M | 61.74% | ↗ |
| 11 | 2023 | Bruce Car Chief Scientific Officer | 489.9K | 385.8K | — | 1.70M | — | 7.4K | 2.58M | 65.83% | ↗ |
| 12 | 2023 | Bruce Car, Ph.D. Chief Scientific Officer | 489.9K | 385.8K | — | 1.70M | — | 7.4K | 2.58M | 65.83% | ↗ |
| 13 | 2023 | Kimberly Gentile Senior Vice President, Clinical Operations | 470.5K | 370.5K | — | 1.70M | — | 17.7K | 2.56M | 66.46% | ↗ |
| 14 | 2022 | Vlad Coric, M.D. Chief Executive Officer | 200.0K | 1.05M | — | 4.72M | — | 705.00 | 5.97M | 79.06% | ↗ |
| 15 | 2022 | Matthew Buten Chief Financial Officer | 131.3K | 413.4K | — | 1.49M | — | 1.0K | 2.04M | 73.20% | ↗ |
| 16 | 2022 | Bruce Car, Ph.D. Chief Scientific Officer | 121.3K | 160.1K | — | 1.49M | — | 1.8K | 1.77M | 84.04% | ↗ |
| 17 | 2022 | Bruce Car Chief Scientific Officer | 121.3K | 160.1K | — | 1.49M | — | 1.8K | 1.77M | 84.04% | ↗ |
| 18 | 2021 | Vlad Coric, M.D. Chief Executive Officer | 750.0K | 1.05M | 4.17M | 4.94M | — | 14.0K | 10.92M | 83.40% | ↗ |
| 19 | 2021 | Matthew Buten Chief Financial Officer | 33.8K | 15.2K | 5.27M | — | — | — | 5.32M | 99.08% | ↗ |
| 20 | 2021 | William Jones, Jr. Chief Commercial Officer of Migraine & Common Diseases | 507.2K | 507.2K | 1.67M | 1.98M | — | 28.7K | 4.69M | 77.75% | ↗ |
| 21 | 2021 | Elyse Stock Chief Medical Officer | 491.5K | 636.1K | 1.25M | 1.48M | — | 19.0K | 3.88M | 70.45% | ↗ |
| 22 | 2021 | Kimberly Gentile Senior Vice President, Clinical Operations | 430.0K | 587.7K | 1.25M | 1.48M | — | 13.6K | 3.76M | 72.60% | ↗ |
| 23 | 2021 | James Engelhart Former Chief Financial Officer | 452.6K | 356.4K | 1.25M | 1.48M | — | 15.6K | 3.56M | 76.82% | ↗ |
| 24 | 2020 | Vlad Coric, M.D. Chief Executive Officer | 621.5K | 621.5K | — | — | — | 16.2K | 1.26M | 0.00% | ↗ |
| 25 | 2020 | William Jones, Jr. Chief Commercial Officer of Migraine & Common Diseases | 483.0K | 422.6K | — | — | — | 26.2K | 931.8K | 0.00% | ↗ |
| 26 | 2020 | Elyse Stock Chief Medical Officer | 434.9K | 266.4K | — | — | — | 25.4K | 726.8K | 0.00% | ↗ |
| 27 | 2020 | James Engelhart Chief Financial Officer | 435.2K | 266.5K | — | — | — | 15.3K | 717.0K | 0.00% | ↗ |
| 28 | 2020 | James Engelhart Former Chief Financial Officer | 435.2K | 266.5K | — | — | — | 15.3K | 717.0K | 0.00% | ↗ |
| 29 | 2020 | Kimberly Gentile Senior Vice President, Clinical Operations | 390.9K | 239.4K | — | — | — | 24.6K | 655.0K | 0.00% | ↗ |
| 30 | 2019 | Vlad Coric, M.D. Chief Executive Officer | 550.0K | 581.3K | 2.51M | 3.13M | — | 13.4K | 6.79M | 83.14% | ↗ |
| 31 | 2019 | William Jones, Jr. Chief Commercial Officer of Migraine & Common Diseases | 345.0K | 936.0K | 688.8K | 3.62M | — | 14.5K | 5.61M | 76.89% | ↗ |
| 32 | 2019 | Kimberly Gentile Senior Vice President, Clinical Operations | 372.3K | 228.0K | 861.0K | 1.21M | — | 13.7K | 2.68M | 77.09% | ↗ |
| 33 | 2019 | James Engelhart Chief Financial Officer | 406.7K | 234.9K | 849.5K | 1.05M | — | 14.8K | 2.56M | 74.37% | ↗ |
| 34 | 2019 | James Engelhart Former Chief Financial Officer | 406.7K | 234.9K | 849.5K | 1.05M | — | 14.8K | 2.56M | 74.37% | ↗ |
| 35 | 2019 | Elyse Stock Chief Medical Officer | 378.2K | 198.6K | 774.9K | 1.10M | — | 17.6K | 2.47M | 75.91% | ↗ |
| 36 | 2018 | Vlad Coric, M.D. Chief Executive Officer | 500.0K | 437.5K | — | 4.34M | — | 12.5K | 5.29M | 82.06% | ↗ |
| 37 | 2018 | Charles Conway, Ph.D. Chief Scientific Officer | 335.0K | 205.2K | — | 2.24M | — | 8.9K | 2.79M | 80.34% | ↗ |
| 38 | 2018 | Kimberly Gentile SVP, Clinical Operations | 327.3K | 198.3K | — | 2.24M | — | 15.2K | 2.78M | 80.58% | ↗ |
| 39 | 2018 | James Engelhart Chief Financial Officer | 380.8K | 233.2K | — | 1.63M | — | 14.0K | 2.26M | 72.18% | ↗ |
| 40 | 2018 | Kimberly Gentile Senior Vice President, Clinical Operations | 327.3K | 198.3K | — | 1.41M | — | 15.2K | 1.95M | 72.31% | ↗ |
| 41 | 2018 | John Tilton Chief Commercial Officer | 309.0K | 162.2K | — | 1.04M | — | 18.8K | 1.53M | 67.88% | ↗ |
| 42 | 2017 | Vlad Coric, M.D. Chief Executive Officer | 420.9K | 337.5K | — | 3.09M | — | 10.8K | 3.86M | 80.05% | ↗ |
| 43 | 2017 | James Engelhart Chief Financial Officer | 327.0K | 178.5K | — | 1.99M | — | 13.1K | 2.51M | 79.34% | ↗ |
| 44 | 2017 | Charles Conway, Ph.D. Chief Scientific Officer | 305.9K | 191.9K | — | 1.12M | — | 9.9K | 1.63M | 68.78% | ↗ |
| 45 | 2016 | Vlad Coric, M.D. Chief Executive Officer | 350.0K | 245.0K | — | 189.4K | — | — | 784.4K | 24.15% | ↗ |
| 46 | 2016 | James Engelhart Chief Financial Officer | 222.6K | 137.0K | — | 118.3K | — | 4.9K | 482.8K | 24.50% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Vladimir Coric | Chairman & Chief Executive Officer | 1M | — |
| Matthew Buten | Chief Financial Officer | 858.6K | male |
| Bruce D. Car DACVP | Chief Scientific Officer | 801.4K | — |
| Kimberly Gentile | Senior Vice President of Clinical Operations | 757.7K | female |
| Jennifer Porcelli | Vice President of Investor Relations | — | female |
| John McGill | Chief Technology Officer | — | male |
| Warren Volles | General Counsel & Chief Legal Officer | — | male |
| Clifford Bechtold | President, GM of Biohaven Ireland & Chief Compliance Officer | — | male |
| Deb Young | Senior Director of Regulatory Affairs & Operations | — | female |
| George C. Clark | Vice President & Chief Accounting Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BHVN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
